Hamsters Develop Protective Immunity to COVID-19 and Are Protected by Convalescent Sera

Jul 1 | News, Research

By Kelly April Tyrrell, University Communications, University of Wisconsin-Madison

In an animal model for COVID-19 that shares important features of human disease, scientists at the University of Wisconsin-Madison, the University of Tokyo and the Icahn School of Medicine at Mount Sinai show that prior infection with the SARS-CoV-2 virus provides protection against reinfection, and treatment with convalescent serum limits virus replication in their lungs.

Syrian hamsters, commonly found as pets, have served critical roles in understanding human infectious diseases for decades. The new study, led by Dr. Yoshihiro Kawaoka and published June 22, 2020, in the Proceedings of the National Academy of Sciences, demonstrates they are also a useful small animal model for researchers trying to understand SARS-CoV-2 and in evaluating vaccines, treatments and drugs against the disease it causes.

“Hamsters are good models for human influenza and SARS-CoV,” says Dr. Kawaoka, professor of pathobiological sciences at the UW School of Veterinary Medicine and a virology professor at the University of Tokyo. “This is why we decided to study them with COVID-19. We wanted to see if the disease course is similar to humans in these animals from beginning to end.”

Dr. Kawaoka’s group demonstrated that both low and high doses of the virus, from patient samples collected in the U.S. and Japan, replicate well in the airways of juvenile and adult hamsters. The virus can also infect both the upper and lower respiratory tracts.

The research team also showed that SARS-CoV-2 causes severe disease in the lungs of infected animals. This includes lesions and the kind of “ground glass” appearance often found in lung scans in human patients. Scans also revealed a region of gas in the cavity surrounding the hamster’s lungs, indicating severe lung damage. Researchers observed the most severe effects within eight days after infection, and improvement by 10 days.

“Hamsters infected with SARS-CoV-2 share CT imaging characteristics with human COVID-19 disease,” says Dr. Samantha Loeber, a veterinarian and radiologist at UW Veterinary Care.

By day 10 following infection, the researchers no longer detected virus in the organs of most of the hamsters, but lung damage persisted for 14 days in a majority of the animals, and for at least 20 days in most of those infected with a high dose.

To determine whether hamsters developed antibodies against SARS-CoV-2 that protected them from reinfection, the researchers administered another round of the virus to a number of the same animals about three weeks following initial infection. They were unable to detect virus in their respiratory tracts. They did find virus in the airways of control animals not previously infected.

“The animals all possessed antibodies and did not get sick again, which suggests they developed protective immunity,” says Dr. Peter Halfmann, a research professor in Dr. Kawaoka’s U.S. lab. “But we still can’t say how long this protection lasts.”

In early April, researchers across the U.S., including at the UW School of Medicine and Public Health and UW Health, initiated a clinical trial to examine whether the antibody-bearing component of blood – the plasma or sera – from recovered COVID-19 patients could be given to sick patients to assist in their recovery. While convalescent plasma has been used in other disease outbreaks, it remains poorly understood as a treatment.

So, Dr. Kawaoka’s team extracted convalescent sera from previously sick hamsters and then pooled it together. They infected new hamsters with SARS-CoV-2 and then gave them this antibody-laden sera either one day or two days following infection.

The hamsters that received treatment within a day of infection had much lower amounts of infectious virus in their nasal passages and lungs than those given a mock treatment. Those that received sera on day two showed a less appreciable benefit, though they still had lower levels of virus in their respiratory organs compared to control animals.

“This shows us that convalescent sera, still experimental in human patients, may be part of an effective treatment for COVID-19,” Dr. Kawaoka adds.

Finally, the research team also obtained the first images of the internal features of the SARS-CoV-2 virus that aid its ability to replicate, or make copies of itself, in host cells. This, Dr. Kawaoka says, warrants further study.